SIRPA and ovarian carcinoma: ALX‐148 specifically blocks the cd47 receptor, and since CD47/SIRPα axis additionally constrains the efficacy of tumour‐opsonising antibodies, a combination therapy pf ALX‐148 and other anticancer drug could boost their effect in platinum‐resistant ovarian cancer.